Hemostemix Inc. (CVE:HEM – Get Free Report) shares hit a new 52-week high during trading on Thursday . The company traded as high as C$0.32 and last traded at C$0.31, with a volume of 982216 shares traded. The stock had previously closed at C$0.28.
Hemostemix Stock Performance
The business has a 50-day moving average price of C$0.12 and a 200 day moving average price of C$0.09. The stock has a market capitalization of C$30.49 million, a P/E ratio of -17.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- 3 Tickers Leading a Meme Stock Revival
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- How to Invest in Small Cap StocksÂ
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.